荣泰健康
(603579)
| 流通市值：41.95亿 | | | 总市值：41.95亿 |
| 流通股本：1.77亿 | | | 总股本：1.77亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,164,316,596.07 | 824,918,018.49 | 400,613,890.42 | 1,855,029,390.81 |
| 营业收入 | 1,164,316,596.07 | 824,918,018.49 | 400,613,890.42 | 1,855,029,390.81 |
| 二、营业总成本 | 1,027,733,709.64 | 716,349,779.94 | 331,559,198.75 | 1,641,615,183.82 |
| 营业成本 | 786,711,497.71 | 551,293,930.67 | 256,891,135.34 | 1,283,241,376.66 |
| 税金及附加 | 9,870,840.75 | 5,572,085.08 | 2,748,306.17 | 10,094,878.33 |
| 销售费用 | 125,232,032.89 | 90,107,784.79 | 39,277,080.03 | 204,444,174.34 |
| 管理费用 | 57,521,268.96 | 41,738,443.48 | 20,521,223.62 | 78,547,495.6 |
| 研发费用 | 57,007,658.8 | 38,122,653.47 | 20,142,315.83 | 80,176,150.48 |
| 财务费用 | -8,609,589.47 | -10,485,117.55 | -8,020,862.24 | -14,888,891.59 |
| 其中:利息费用 | 3,591,417.78 | 2,132,660.95 | 742,926.04 | 27,407,578.53 |
| 其中:利息收入 | 12,631,875.27 | 10,030,607.88 | 6,936,784.12 | 34,843,493.34 |
| 加:公允价值变动收益 | -920,780.53 | 2,588,809.68 | 640,110.25 | -16,218,630.62 |
| 加:投资收益 | 18,344,311.54 | 8,605,112.96 | -1,932,491.35 | 29,264,055.28 |
| 资产处置收益 | -109,812.47 | -109,812.47 | -13,508.33 | -951,752.36 |
| 资产减值损失(新) | -1,910,238.52 | -434,965.22 | -324,284.6 | -6,615,134.13 |
| 信用减值损失(新) | -1,436,988.53 | -2,018,344.73 | 566,690.13 | -139,155.67 |
| 其他收益 | 7,290,170.52 | 4,808,404.89 | 1,262,583.94 | 17,201,548.67 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 157,839,548.44 | 122,007,443.66 | 69,253,791.71 | 235,955,138.16 |
| 加:营业外收入 | 124,278.85 | 122,088.05 | 27,547.24 | 955,477.57 |
| 减:营业外支出 | 380,085.09 | 376,832.3 | 17,647.26 | 6,718,952.81 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 157,583,742.2 | 121,752,699.41 | 69,263,691.69 | 230,191,662.92 |
| 减:所得税费用 | 14,791,959.18 | 10,378,826.83 | 6,416,345.43 | 26,859,754.72 |
| 六、净利润 | 142,791,783.02 | 111,373,872.58 | 62,847,346.26 | 203,331,908.2 |
| 持续经营净利润 | 142,791,783.02 | 111,373,872.58 | 62,847,346.26 | 203,331,908.2 |
| 归属于母公司股东的净利润 | 142,512,054.98 | 111,336,627.48 | 62,741,790.01 | 202,706,851.03 |
| 少数股东损益 | 279,728.04 | 37,245.1 | 105,556.25 | 625,057.17 |
| (一)基本每股收益 | 0.82 | 0.64 | 0.47 | 1.51 |
| (二)稀释每股收益 | 0.72 | 0.58 | 0.42 | 1.47 |
| 八、其他综合收益 | -7,756,276.24 | -18,903,963.89 | -1,894,057.5 | 47,771,029.86 |
| 归属于母公司股东的其他综合收益 | -7,715,397.18 | -18,872,732.92 | -1,898,713.12 | 47,754,922.4 |
| 九、综合收益总额 | 135,035,506.78 | 92,469,908.69 | 60,953,288.76 | 251,102,938.06 |
| 归属于母公司股东的综合收益总额 | 134,796,657.8 | 92,463,894.56 | 60,843,076.89 | 250,461,773.43 |
| 归属于少数股东的综合收益总额 | 238,848.98 | 6,014.13 | 110,211.87 | 641,164.63 |
| 公告日期 | 2024-10-30 | 2024-08-28 | 2024-04-26 | 2024-04-16 |
| 审计意见(境内) | | | | 标准无保留意见 |